Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background: Prazosin has been an accepted treatment for patients with post-traumatic stress disorder (PTSD) who experience sleep disturbances, including nightmares. Results of a recent large randomized control trial did not find benefit of prazosin vs placebo in improving such outcomes. A meta-analysis that includes this most recent trial was conducted to examine the pooled effect of prazosin vs placebo on sleep disturbances and overall PTSD symptoms in patients with PTSD. Methods: A systematic review of the published literature on trials comparing prazosin vs placebo for improvement of overall PTSD scores, nightmares, and sleep quality was conducted. Hedges’ g standardized mean differences (SMD) between prazosin and placebo were calculated for each outcome across studies. Results: Six randomized placebo-controlled studies representing 429 patients were included in the analysis, including two studies with a crossover design. Results showed prazosin significantly improved overall PTSD scores (SMD = −0.31; 95% confidence intervals [CI]: −0.62, −0.01), nightmares (SMD = −0.75; 95% CI: −1.24, −0.27), and sleep quality (SMD = −0.57; 95% CI: −1.02, −0.13). In the largest trial, prazosin showed a reduction in clinical outcome measures similar to past studies, but a relatively large placebo effect size, particularly for nightmares, contributed to no treatment differences. Conclusions: Despite the results of a recent, large randomized study, pooled effect estimates show that prazosin has a statistically significant benefit on PTSD symptoms and sleep disturbances. Limitations that should be considered include heterogeneity of study design and study populations as well as the small number of studies conducted and included in this meta-analysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is supported by a recent meta-analysis [35] confirming that prazosin does have a statistically significant benefit on PTSD symptoms and sleep disturbances.”
From Nightmare Disorder and Isolated Sleep Paralysis (2021) · cites this paper as [35]
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Statistical Methods for Meta-Analysis.
Freeman, P. R., Hedges, L. V., & Olkin, I. (1986) · Biometrics · doi:10.2307/2531069 · Cited by 4,784
Psychometric properties of the PTSD checklist (PCL)
Blanchard, E. B., Jones-Alexander, J., Buckley, T. C., & Forneris, C. A. (1996) · Behaviour Research and Therapy · doi:10.1016/0005-7967(96)00033-2 · Cited by 3,997 · cited 1×
“Overall PTSD score was assessed using Clinician-Administered PTSD Scale (CAPS)(23) or PTSD checklist-Civilian (PCL-C).(24) Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI)(25) scales and CAPS item 13, while nightmares were assessed using questions from CAPS and PSQI and/or sleep diary informa…”
MethodPsychotherapy for Military-Related PTSD: A Review of Randomized Clinical Trials
Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015) · JAMA · doi:10.1001/jama.2015.8370 · Cited by 958 · cited 1×
“Unfortunately, these treatments often fall short of treatment goals and many individuals suffer persistent symptoms, including sleep disturbances, that are associated with substantial disability.(6,7) As a result, there has been an urgent need for innovation in developing therapies to treat PTSD and its related sympto…”
BackgroundRaskind, M. A., Peskind, E. R., Kanter, E. D., Petrie, E. C., Radant, A., Thompson, C. E., Dobie, D. J., Hoff, D., Rein, R. J., Straits-Tröster, K., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.371 · Cited by 607 · cited 1×
“Successful trials and case reports have reported that prazosin treatment is related to improvement in these specific symptoms.(8,14,28,29,31,37) Does the single, large Raskind et al’s study(15) completely negate the previous literature? Our random effects meta-analyses indicate that it does not.”
BackgroundRaskind, M. A., Peskind, E. R., Hoff, D. J., Hart, K. L., Holmes, H. A., Warren, D., Shofer, J., O’Connell, J., Taylor, F., Gross, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.032 · Cited by 552
Raskind, M. A., Peterson, K., Williams, T., Hoff, D. J., Hart, K., Holmes, H., Homas, D., Hill, J., Daniels, C., Calohan, J., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12081133 · Cited by 355 · cited 1×
“Successful trials and case reports have reported that prazosin treatment is related to improvement in these specific symptoms.(8,14,28,29,31,37) Does the single, large Raskind et al’s study(15) completely negate the previous literature? Our random effects meta-analyses indicate that it does not.”
BackgroundPharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.004 · Cited by 347 · cited 1×
“Unfortunately, these treatments often fall short of treatment goals and many individuals suffer persistent symptoms, including sleep disturbances, that are associated with substantial disability.(6,7) As a result, there has been an urgent need for innovation in developing therapies to treat PTSD and its related sympto…”
BackgroundTrial of prazosin for post-traumatic stress disorder in military veterans
Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., Hart, K. L., McFall, M., Mellman, T. A., Reist, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1507598 · Cited by 342 · cited 4×
“A m on g al lo ut co m es ,n o ad ve rs e ef fe ct w as de m on st ra te d an d al ld at a w as ob ta in ed w it h re sp ec t to th at ou tc om e m ea su re . even with inclusion of Raskind et al.15 Did the “negative finding” in that study reflect poor outcomes in patients treated with prazosin?”
BackgroundResultInfluentialSelf-citationTaylor, F. B., Martin, P., Thompson, C., Williams, J., Mellman, T. A., Gross, C., Peskind, E. R., & Raskind, M. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.07.001 · Cited by 336 · cited 2×
“1mg per day.(9) Results of the meta-analyses showed that, compared to the placebo arms, prazosin treatment resulted in a significant decrease of overall PTSD symptoms (SMD= 0.”
BackgroundResultBirnbaum, S., Gobeske, K. T., Auerbach, J., Taylor, J. R., & Arnsten, A. F. T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00138-9 · Cited by 281
Friedman, M. J., Marmar, C. R., Baker, D. G., Sikes, C. R., & Farfel, G. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0508 · Cited by 242
Morgenthaler, T. I., Auerbach, S., Casey, K. R., Kristo, D., Maganti, R., Ramar, K., Zak, R., & Kartje, R. (2018) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7178 · Cited by 230
Germain, A., Richardson, R., Moul, D. E., Mammen, O., Haas, G., Forman, S. D., Rode, N., Begley, A., & Nofzinger, E. A. (2012) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2011.11.010 · Cited by 229
Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD)
Ipser, J. C., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001209 · Cited by 216
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 214
Ryder, A. L., Azcarate, P. M., & Cohen, B. E. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0977-9 · Cited by 190
Raskind, M. A., Dobie, D. J., Kanter, E. D., Petrie, E. C., Thompson, C. E., & Peskind, E. R. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0208 · Cited by 154 · cited 1×
“Successful trials and case reports have reported that prazosin treatment is related to improvement in these specific symptoms.(8,14,28,29,31,37) Does the single, large Raskind et al’s study(15) completely negate the previous literature? Our random effects meta-analyses indicate that it does not.”
BackgroundPharmacologic Reduction of CNS Noradrenergic Activity in PTSD: The Case for Clonidine and Prazosin
BOEHNLEIN, J. K., & KINZIE, J. D. (2007) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000265763.79753.c1 · Cited by 140
Nash, W. P., & Watson, P. J. (2012) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2011.10.0194 · Cited by 117
Berardis, D., Marini, S., Serroni, N., Iasevoli, F., Tomasetti, C., Bartolomeis, A., Mazza, M., Tempesta, D., Valchera, A., Fornaro, M., et al. (2015) · Current Drug Targets · doi:10.2174/1389450116666150506114108 · Cited by 112
Khachatryan, D., Groll, D., Booij, L., Sepehry, A. A., & Schütz, C. G. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.10.007 · Cited by 104 · cited 1×
“The search terms were similar to those listed in a prior published meta-analysis.(13) To find additional articles that may not have been PubMed indexed, a similar query was used to searchWeb of Science, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Cochrane Central Register of Controll…”
MethodPsychiatric symptoms of noradrenergic dysfunction: A pathophysiological view
Yamamoto, K., Shinba, T., & Yoshii, M. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12126 · Cited by 88
Causes of Excess Mortality in Veterans Treated for Posttraumatic Stress Disorder
Forehand, J. A., Peltzman, T., Westgate, C. L., Riblet, N. B., Watts, B. V., & Shiner, B. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.03.014 · Cited by 85 · cited 1×
“PTSD has been associated with worsening physical function,(2) development of chronic conditions,(3,4) and increasedmortality risk.(5) Patients suffering from PTSD have a number of evidence-based treatment options.”
BackgroundRole of norepinephrine in the regulation of rapid eye movement sleep
Mallick, B. N., Majumdar, S., Faisal, M., Yadav, V., Madan, V., & Pal, D. (2002) · Journal of Biosciences · doi:10.1007/bf02705052 · Cited by 81
Hoerster, K. D., Campbell, S. B., Dolan, M., Stappenbeck, C. A., Yard, S. S., Simpson, T. L., & Nelson, K. M. (2019) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2019.100930 · Cited by 77
George, K. C., Kebejian, L., Ruth, L. J., Miller, C. W. T., & Himelhoch, S. (2016) · Journal of Trauma & Dissociation · doi:10.1080/15299732.2016.1141150 · Cited by 75
Efficacy of Prazosin in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis
Singh, B., Hughes, A. J., Mehta, G., Erwin, P. J., & Parsaik, A. K. (2016) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.16r01943 · Cited by 55 · cited 1×
“Successful trials and case reports have reported that prazosin treatment is related to improvement in these specific symptoms.(8,14,28,29,31,37) Does the single, large Raskind et al’s study(15) completely negate the previous literature? Our random effects meta-analyses indicate that it does not.”
BackgroundVythilingam, M. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.11.4138 · Cited by 51 · cited 1×
“As an α1-adrenergic receptor antagonist, prazosin blocks noradrenergic activity in the central nervous system(32) in areas related to hyperarousal of symptoms typical of PTSD, including irritability,(33) sleep disturbances,(34) increased cognitive processing and fear response,(35) and related release of cortisol.(36)…”
BackgroundDaly, C. M., Doyle, M. E., Radkind, M., Raskind, E., & Daniels, C. (2005) · Military Medicine · doi:10.7205/milmed.170.6.513 · Cited by 49 · cited 1×
“Successful trials and case reports have reported that prazosin treatment is related to improvement in these specific symptoms.(8,14,28,29,31,37) Does the single, large Raskind et al’s study(15) completely negate the previous literature? Our random effects meta-analyses indicate that it does not.”
BackgroundHall, K. S. M., Beckham, J. C., Bosworth, H. B., Sloane, R. J., Pieper, C. F., & Morey, M. C. (2014) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2013.04.0091 · Cited by 44
Alpha-Adrenergic Receptors in PTSD — Failure or Time for Precision Medicine?
Ressler, K. J. (2018) · New England Journal of Medicine · doi:10.1056/nejme1716724 · Cited by 23
Prazosin for Post-Traumatic Stress Disorder.
Raskind, M. A., & Peskind, E. R. (2018) · PubMed · doi:10.1056/nejmc1803171 · Cited by 6
Prazosin May Not Reduce Nightmares in Veterans With PTSD
Slomski, A. J. (2018) · JAMA · doi:10.1001/jama.2018.4741 · Cited by 1
Research works printed but not linked: 3
- Glue, 2018, Prazosin for post-traumatic stress disorder, N Engl J Med, 378, 1649
- Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions Vol. Version 5.1.0
- Mysliwiec, 2018, Prazosin for post-traumatic stress disorder, N Engl J Med, 378, 1649
Cited by
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Noradrenergic circuit control of non-REM sleep substates
Osorio-Forero, A., Cardis, R., Vantomme, G., Guillaume-Gentil, A., Katsioudi, G., Devenoges, C., Fernandez, L. M. J., & Lüthi, A. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.041 · Cited by 230
Post-traumatic Stress Disorder
Merians, A. N., Spiller, T. R., Harpaz‐Rotem, I., Krystal, J. H., & Pietrzak, R. H. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.04.003 · Cited by 132
Schnurr, P. P., Hamblen, J. L., Wolf, J., Coller, R., Collie, C. F., Fuller, M. A., Holtzheimer, P. E., Kelly, U. A., Lang, A. J., McGraw, K., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2757 · Cited by 112
“Three RCTs reviewed as part of the 2017 CPG for PTSD and ASD (67 – 69), plus a systematic review and 2 additional RCTs identi fi ed in the current evidence review (70 – 72), suggest that delivery of CPT and PE via video tele-conferencing is noninferior to face-to-face delivery.”
BackgroundNightmare Disorder and Isolated Sleep Paralysis
Stefani, A., & Högl, B. (2021) · Neurotherapeutics · doi:10.1007/s13311-020-00966-8 · Cited by 66
Metadata
- Authors
- Reist, C., Streja, E., Tang, C. C., Shapiro, B., Mintz, J., & Hollifield, M.
- Affiliations
- University of California, Irvine (US)
- The University of Texas at San Antonio Health Science Center (US)
- Tibor Rubin VA Medical Center (US)
- Corresponding author
- Reist, Christopher
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2020-05-04
- Volume
- 26
- Issue
- 4
- Pages
- 338-344
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W3023536591
- Cited by
- 56
- References
- 37
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 17 · 2023: 13 · 2022: 7 · 2021: 5 · 2020: 1
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Spectrums (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Keywords
- prazosin, post-traumatic stress disorder, nightmares, sleep disorders, sleep quality, placebo effect, alpha-blockers, PTSD symptom severity
- MeSH terms
- Humans, Prazosin, Stress Disorders, Post-Traumatic, Treatment Outcome, Adrenergic alpha-1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.